Safir02-breast immuno
WebThe SAFIR02-BREAST IMMUNO substudy included patients with human epidermal growth factor receptor type 2 (Her2)-negative metastatic breast cancer whose disease did not … WebJul 2, 2024 · In a substudy of the SAFIR02-IMMUNO trial, 199 patients with metastatic HER2-negative mBC without a targetable mutation and who had SD, ... Durvalumab compared to …
Safir02-breast immuno
Did you know?
WebMay 22, 2024 · Methods: SAFIR02 BREAST IMMUNO randomized 199 pts presenting a MBC without actionable genomic alterations, responding to 6 months standard chemotherapy, … WebPD(L)1 inhibitor have shown efficacy for limited sub population of patients (pts) with HER2 negative metastatic breast cancer (MBC). The main predictive marker of efficacy to date …
WebThomas Bachelot, MD, PhD, of Centre Léon Bérard, Lyon, France, discusses a subgroup analyses of the SAFIR02-IMMUNO study (NCT02299999) which aimed to determi... WebJan 21, 2024 · PD-L1 is a ligand protein produced by tumor cells that binds PD-1 to attenuate T-cell-mediated immunosurveillance and provide an immune escape from cancer cells [ …
WebDec 8, 2024 · SAFIR02-BREAST (ClinicalTrials.gov Identifier: NCT02299999) is a phase 2 trial that included 1462 patients with metastatic, HER2-negative breast cancer. WebDec 9, 2024 · The researchers identified 207 participants of the SAFIR02-Breast study who had stable disease after 6–8 cycles of induction chemotherapy and an actionable …
WebFeb 15, 2024 · As a substudy of the SAFIR02-breast trial, the SAFIR02-IMMUNO trial has its primary endpoint, the PFS, hierarchized as the primary end-point of the core of the study. …
SAFIR02-BREAST IMMUNO is a phase II interventional randomized open-label trial that compares durvalumab (10 mg kg−1 every 2 weeks until progressive disease or toxicity) with maintenance chemotherapy in patients who do not present an actionable genomic alteration. The first patient was randomized … See more Patients signed the informed consent for randomization and were treated either by intravenous durvalumab (10 mg kg−1 every 2 weeks) or … See more The tumor samples were qualified for further genomic testing if more than 30% of the cells in the biopsy sample were cancer cells for frozen … See more ER, PR and Her2 statuses were determined locally. ER and PR thresholds for positivity were set at 1% of tumor cells. ER and PR determinations were assessed on the primary tumor samples. Her2 was defined according to … See more Copy number variations from CytoScan and OncoScan were defined using the R package rCGH31 (v1.16.0, under R v3.6.3). Briefly, log2 relative ratios was calculated, a centralization of the profile set the baseline (two copies … See more clint smith pueblo coWebRT @DrChoueiri: Randomized phase II Durvalumab vs. chemo in metastatic breast ca (SAFIR02-BREAST IMMUNO trial ) in @NatureMedicine Congrats @FAndreMD + team! … bobcat t190 final drive rebuild kitWebJan 10, 2024 · The BCRF researcher breaks down recent results from the SAFIR02-BREAST trial (presented at SABCS 2024) how tumor profiling has changed breast cancer care, and … bobcat t190 bobtachWebNov 24, 2014 · SAFIR02_Breast - Efficacy of ... If not eligible for the substudy 1 randomisation phase, patients can be considered as pre-eligible for the immune substudy … bobcat t190 engineWebFeb 25, 2024 · Given as maintenance therapy, the checkpoint inhibitor durvalumab significantly improved overall survival in patients with metastatic triple-negative breast … bobcat t190 forestry mulcherWebSep 23, 2024 · Therefore, new maintenance therapies are warranted to improve the survival of advanced-stage or metastatic cancer patients. In recent years, immune checkpoint … clint smith quotes thunder ranchWebThe impact of single-agent antibodies against programmed death-ligand 1 (PD-L1) as maintenance therapy is unknown in patients with metastatic breast cancer. The SAFIR02 … bobcat t190 alternator belt length